CoChat

GLP-1R Signaling and Functional Molecules in Incretin Therapy

Open access

The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes mellitus (T2DM). The GLP-1R cellular signaling mechanism relevant to insulin secretion and blood glucose regulation has been extensively studied. Numerous drugs targeting GLP-1R have entered clinical treatment. However, novel functional molecules with reduced side effects and enhanced therapeutic efficacy are still in high demand. In this review, we summarize the basis of GLP-1R cellular signaling, and how it is involved in the treatment of T2DM. We review the functional molecules of incretin therapy in various stages of clinical trials. We also outline the current strategies and emerging techniques that are furthering the development of novel therapeutic drugs for T2DM and other metabolic diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules28020751

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Signaling pathways of GLP-1R in pancreatic β-cell [15,30]. Three downstream signaling pathways initiated from Gαs (blue), Gαq (pink), and β-arrestin (green) are shown in the left half of the β-cell. The GLP-1R internalization process and insulin secretion after GLP-1R activation are also shown. Colored circles show mono-agonists targeting GLP-1R (red), GIPR (green), and GCGR (blue), and multi-agonists targeting GLP-1R/GIPR (red/green), GLP-1R/GCGR (red/blue), and GLP-1R/GIPR/GCGR (red/green/blue). The top left inset shows the structure of GLP-1R with a seven-transmembrane helix bundle and a large ECD. Abbreviations: VDCC, voltage-dependent calcium channel; TRPM, the transient receptor potential melastatin; GCGR, glucagon receptor; GIPR, gastric inhibitory polypeptide receptor.
Figure 1 Signaling pathways of GLP-1R in pancreatic β-cell [15,30]. Three downstream signaling pathways initiated from Gαs (blue), Gαq (pink), and β-arrestin (green) are shown in the left half of the β-cell. The GLP-1R internalization process and insulin secretion after GLP-1R activation are also shown. Colored circles show mono-agonists targeting GLP-1R (red), GIPR (green), and GCGR (blue), and multi-agonists targeting GLP-1R/GIPR (red/green), GLP-1R/GCGR (red/blue), and GLP-1R/GIPR/GCGR (red/green/blue). The top left inset shows the structure of GLP-1R with a seven-transmembrane helix bundle and a large ECD. Abbreviations: VDCC, voltage-dependent calcium channel; TRPM, the transient receptor potential melastatin; GCGR, glucagon receptor; GIPR, gastric inhibitory polypeptide receptor.CC BY · PubMed Central
Figure 2 Development strategies for GLP-1R ligands [16,52,53]. (A) Amino acid sequences of GLP-1 (7-36) amide, exendin-4, and oxyntomodulin. Different residues from GLP-1 are in bold type. DPP-4 deactivates the GLP-1 (7-36) amide by cleaving it after the second amino acid (alanine) from the N-terminal and leads to the short circulation time of GLP-1 (7-36) in human body. (B) Several chemical modifications and their combinations can be applied in GLP-1R peptide agonist development, including C-terminal amidation, acylation, PEGylation, and substitution. (C) GLP-1R peptide ligands can fuse to Fc region of antibody, antibody, and albumin. (D) Three typical small-molecule agonists for GLP-1R: LY-3502970 and PF-06882961 are under clinical trials, while TT-OAD2 has failed.
Figure 2 Development strategies for GLP-1R ligands [16,52,53]. (A) Amino acid sequences of GLP-1 (7-36) amide, exendin-4, and oxyntomodulin. Different residues from GLP-1 are in bold type. DPP-4 deactivates the GLP-1 (7-36) amide by cleaving it after the second amino acid (alanine) from the N-terminal and leads to the short circulation time of GLP-1 (7-36) in human body. (B) Several chemical modifications and their combinations can be applied in GLP-1R peptide agonist development, including C-terminal amidation, acylation, PEGylation, and substitution. (C) GLP-1R peptide ligands can fuse to Fc region of antibody, antibody, and albumin. (D) Three typical small-molecule agonists for GLP-1R: LY-3502970 and PF-06882961 are under clinical trials, while TT-OAD2 has failed.CC BY · PubMed Central
Figure 3 Comparison of peptide and small molecule binding pockets. (A) Structures of GLP1R in complex with GLP1 (PDB: 6X18), tirzepatide (PDB: 7RGP), danuglipron (PDB: 6X1A), LY3502970 (PDB: 7E14), and TT-OAD2 (PDB: 6ORV) are shown in the separated ECD and TMD. GLP-1R is shown as a gray surface model. Residues within 4 Å of the corresponding ligand are colored in blue. (B) Specific residues that interact with corresponding ligands in a fingerprint array. Ligands in (A) and their interaction fingerprints in (B) appear as follows: GLP-1 (orange), tirzepatide (yellow), danuglipron (green), LY3502970 (red), TT-OAD2 (magenta). N/A, not applicable. ECD was not resolved in TT-OAD2 binding structure.
Figure 3 Comparison of peptide and small molecule binding pockets. (A) Structures of GLP1R in complex with GLP1 (PDB: 6X18), tirzepatide (PDB: 7RGP), danuglipron (PDB: 6X1A), LY3502970 (PDB: 7E14), and TT-OAD2 (PDB: 6ORV) are shown in the separated ECD and TMD. GLP-1R is shown as a gray surface model. Residues within 4 Å of the corresponding ligand are colored in blue. (B) Specific residues that interact with corresponding ligands in a fingerprint array. Ligands in (A) and their interaction fingerprints in (B) appear as follows: GLP-1 (orange), tirzepatide (yellow), danuglipron (green), LY3502970 (red), TT-OAD2 (magenta). N/A, not applicable. ECD was not resolved in TT-OAD2 binding structure.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 168 references

Research works printed but not linked: 1

  1. Buckeridge, 2022, Once-daily oral small molecule GLP-1R agonist PF-07081532 robustly reduces glucose and body weight within 4-6 weeks in adults with type 2 diabetes and non-diabetic adults with obesity, Diabetologia, 65, S60

Cited by

See all 44

Metadata

Authors
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y.
Affiliations
  • ShanghaiTech University (CN)
  • Structure Therapeutics, South San Francisco, CA 94080, USA
Corresponding author
  • Stevens, Raymond C.
  • Liu, Yan
Venue
Molecules
Publisher
MDPI AG
Published
2023-01-11
Volume
28
Issue
2
Pages
751
ISSN
1420-3049 (ISSN-L)
OpenAlex
W4315781708
Cited by
44
References
168
Citations by year
2026: 13 · 2025: 13 · 2024: 12 · 2023: 6
FWCI
1.58
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • ShanghaiTech University (21ZR1442500)
  • Shanghai Municipal Government (21ZR1442500)
  • Shanghai Frontiers Science Center for Biomacromolecules and Precision Medicine at ShanghaiTech University (21ZR1442500)
  • Science and Technology Commission of Shanghai Municipality (21ZR1442500)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
GLP-1 receptor, incretin-based therapy, type 2 diabetes, insulin secretion, blood glucose regulation, GLP-1 receptor agonists, GLP-1 receptor antagonists, drug development, metabolic disorders
MeSH terms
Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Humans, Insulin, Signal Transduction, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.